Health TrialsbyHealthPanel

Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

ConditionsLung CancerWedge ResectionGround-glass Opacity
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFudan University

About this trial

This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who sign the informed consent form and are willing to complete the study according to the plan;

Aged from 18 to 80 years old;

ECOG equals 0 or 1;

Not receiving lung cancer surgery before;

Disqualifiers

Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.

CTR is not between 0.25-0.5 or nodule size greater than 2 cm;

Cannot be completely resected by wedge resection;

Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;

Trial design

Design model

Single group

Treatments tested in this trial

  • Wedge resection

    Procedure/Surgery

    Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.

Treatment groups

286 Participants
are divided into 1 treatment group
Group A: Wedge resectionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

5-year overall survival

The event is defined as the death due to any causes.

Time frame
5 years

Secondary outcomes

1

5-year recurrence-free survival

The event is defined as the tumor recurrence.

Time frame
5 years
2

Postoperative lung function (FEV1)

forced expiratory volume in one second (FEV1)

Time frame
5 years
3

Postoperative lung function

forced vital capacity (FVC)

Time frame
5 years
4

Sites of tumor recurrence and metastasis

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fudan University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: